(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | |||||||||||||||
(Address of principal executive offices) | (Zip Code) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||||||||||||||||||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||||||||||||||||||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||||||||||||||||||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: | ||||||||||||||||||||||||||
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||||||||||||||
Exhibit No. | Description | |||||||
Exhibit 99.1 | ||||||||
Exhibit 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | |||||||
ALLEGRO MICROSYSTEMS, INC. | |||||||||||||||||||||||||||||||||||||||||||||||
Date: | May 10, 2023 | By: | /s/ Derek P. D’Antilio | ||||||||||||||||||||||||||||||||||||||||||||
Derek P. D’Antilio | |||||||||||||||||||||||||||||||||||||||||||||||
Senior Vice President, Chief Financial Officer and Treasurer |
In thousands, except per share data | Quarter | Year | |||||||||||||||||||||||||||
Q4 FY23 | Q3 FY23 | Q4 FY22 | FY23 | FY22 | |||||||||||||||||||||||||
Net Sales | |||||||||||||||||||||||||||||
Automotive | $ | 182,376 | $ | 168,056 | $ | 141,213 | $ | 657,479 | $ | 531,564 | |||||||||||||||||||
Industrial | 57,990 | 50,399 | 34,654 | 196,705 | 133,187 | ||||||||||||||||||||||||
Other | 29,079 | 30,334 | 24,426 | 119,469 | 103,923 | ||||||||||||||||||||||||
Total net sales | $ | 269,445 | $ | 248,789 | $ | 200,293 | $ | 973,653 | $ | 768,674 | |||||||||||||||||||
GAAP Financial Measures | |||||||||||||||||||||||||||||
Gross margin % | 56.8 | % | 57.3 | % | 54.7 | % | 56.1 | % | 53.0 | % | |||||||||||||||||||
Operating margin % | 23.4 | % | 26.4 | % | 15.1 | % | 20.8 | % | 17.8 | % | |||||||||||||||||||
Diluted EPS | $ | 0.32 | $ | 0.33 | $ | 0.13 | $ | 0.97 | $ | 0.62 | |||||||||||||||||||
Non-GAAP Financial Measures | |||||||||||||||||||||||||||||
Gross margin % | 57.8 | % | 58.0 | % | 55.6 | % | 56.8 | % | 54.1 | % | |||||||||||||||||||
Operating margin % | 30.2 | % | 30.3 | % | 23.2 | % | 28.6 | % | 23.2 | % | |||||||||||||||||||
Diluted EPS | $ | 0.37 | $ | 0.35 | $ | 0.21 | $ | 1.28 | $ | 0.78 |
Three-Month Period Ended | Fiscal Year Ended | ||||||||||||||||||||||
March 31, 2023 | March 25, 2022 | March 31, 2023 | March 25, 2022 | ||||||||||||||||||||
(Unaudited) | (Unaudited) | (Unaudited) | |||||||||||||||||||||
Net sales | $ | 240,534 | $ | 163,559 | $ | 812,890 | $ | 619,861 | |||||||||||||||
Net sales to related party | 28,911 | 36,734 | 160,763 | 148,813 | |||||||||||||||||||
Total net sales | 269,445 | 200,293 | 973,653 | 768,674 | |||||||||||||||||||
Cost of goods sold | 100,585 | 72,044 | 348,390 | 286,855 | |||||||||||||||||||
Cost of goods sold to related party | 15,771 | 18,646 | 79,184 | 74,359 | |||||||||||||||||||
Gross profit | 153,089 | 109,603 | 546,079 | 407,460 | |||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Research and development | 41,833 | 32,432 | 150,850 | 121,873 | |||||||||||||||||||
Selling, general and administrative | 48,252 | 46,822 | 194,722 | 150,937 | |||||||||||||||||||
Change in fair value of contingent consideration | (100) | 100 | (2,800) | (2,000) | |||||||||||||||||||
Total operating expenses | 89,985 | 79,354 | 342,772 | 270,810 | |||||||||||||||||||
Operating income | 63,104 | 30,249 | 203,307 | 136,650 | |||||||||||||||||||
Other income (expense): | |||||||||||||||||||||||
Interest expense | (755) | (418) | (2,336) | (2,499) | |||||||||||||||||||
Interest income | 580 | 1,125 | 1,724 | 1,442 | |||||||||||||||||||
Foreign currency transaction gain (loss) | (1,617) | (513) | 980 | (568) | |||||||||||||||||||
(Loss) income in earnings of equity investment | (703) | 215 | (406) | 1,007 | |||||||||||||||||||
Unrealized gains (losses) on marketable securities | 7,476 | (760) | 7,471 | 3,722 | |||||||||||||||||||
Other, net | (164) | 258 | 606 | 992 | |||||||||||||||||||
Income before income taxes | 67,921 | 30,156 | 211,346 | 140,746 | |||||||||||||||||||
Income tax provision | 5,909 | 4,504 | 23,852 | 21,191 | |||||||||||||||||||
Net income | 62,012 | 25,652 | 187,494 | 119,555 | |||||||||||||||||||
Net income attributable to non-controlling interests | 35 | 36 | 137 | 148 | |||||||||||||||||||
Net income attributable to Allegro MicroSystems, Inc. | $ | 61,977 | $ | 25,616 | $ | 187,357 | $ | 119,407 | |||||||||||||||
Net income attributable to Allegro MicroSystems, Inc. per share: | |||||||||||||||||||||||
Basic | $ | 0.32 | $ | 0.13 | $ | 0.98 | $ | 0.63 | |||||||||||||||
Diluted | $ | 0.32 | $ | 0.13 | $ | 0.97 | $ | 0.62 | |||||||||||||||
Weighted average shares outstanding: | |||||||||||||||||||||||
Basic | 191,519,850 | 189,997,738 | 191,197,452 | 189,748,427 | |||||||||||||||||||
Diluted | 194,993,241 | 192,125,252 | 193,688,102 | 191,811,205 |
Three-Month Period Ended | Change | Fiscal Year Ended | Change | ||||||||||||||||||||||||||||||||||||||||||||
March 31, 2023 | March 25, 2022 | Amount | % | March 31, 2023 | March 25, 2022 | Amount | % | ||||||||||||||||||||||||||||||||||||||||
(Dollars in thousands) | |||||||||||||||||||||||||||||||||||||||||||||||
Automotive | $ | 182,376 | $ | 141,213 | $ | 41,163 | 29.1 | % | $ | 657,479 | $ | 531,564 | $ | 125,915 | 23.7 | % | |||||||||||||||||||||||||||||||
Industrial | 57,990 | 34,654 | 23,336 | 67.3 | % | 196,705 | 133,187 | 63,518 | 47.7 | % | |||||||||||||||||||||||||||||||||||||
Other | 29,079 | 24,426 | 4,653 | 19.0 | % | 119,469 | 103,923 | 15,546 | 15.0 | % | |||||||||||||||||||||||||||||||||||||
Total net sales | 269,445 | 200,293 | 69,152 | 34.5 | % | 973,653 | 768,674 | 204,979 | 26.7 | % |
March 31, 2023 | March 25, 2022 | ||||||||||
(Unaudited) | |||||||||||
Assets | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 351,576 | $ | 282,383 | |||||||
Restricted cash | 7,129 | 7,416 | |||||||||
Trade accounts receivable, net of provision for expected credit losses | 111,290 | 87,359 | |||||||||
Trade and other accounts receivable due from related party | 13,494 | 27,360 | |||||||||
Accounts receivable - other | 1,943 | 4,144 | |||||||||
Inventories | 151,301 | 86,160 | |||||||||
Prepaid expenses and other current assets | 25,346 | 14,995 | |||||||||
Current portion of related party note receivable | 3,750 | 1,875 | |||||||||
Total current assets | 665,829 | 511,692 | |||||||||
Property, plant and equipment, net | 263,099 | 210,028 | |||||||||
Operating lease right-of-use assets | 16,866 | 16,049 | |||||||||
Deferred income tax assets | 50,359 | 17,967 | |||||||||
Goodwill | 27,691 | 20,009 | |||||||||
Intangible assets, net | 52,378 | 35,970 | |||||||||
Related party note receivable, less current portion | 8,438 | 5,625 | |||||||||
Equity investment in related party | 27,265 | 27,671 | |||||||||
Other assets, net | 69,230 | 47,609 | |||||||||
Total assets | $ | 1,181,155 | $ | 892,620 | |||||||
Liabilities, Non-Controlling Interests and Stockholders' Equity | |||||||||||
Current liabilities: | |||||||||||
Trade accounts payable | $ | 56,256 | $ | 29,836 | |||||||
Amounts due to related parties | 9,682 | 5,222 | |||||||||
Accrued expenses and other current liabilities | 94,894 | 65,459 | |||||||||
Current portion of operating lease liabilities | 4,493 | 3,706 | |||||||||
Total current liabilities | 165,325 | 104,223 | |||||||||
Obligations due under Senior Secured Credit Facilities | 25,000 | 25,000 | |||||||||
Operating lease liabilities, less current portion | 13,048 | 12,748 | |||||||||
Other long-term liabilities | 10,967 | 15,286 | |||||||||
Total liabilities | 214,340 | 157,257 | |||||||||
Commitments and contingencies | |||||||||||
Stockholders' Equity: | |||||||||||
Preferred Stock, $0.01 par value; 20,000,000 shares authorized, no shares issued or outstanding at March 31, 2023 and March 25, 2022 | — | — | |||||||||
Common stock, $0.01 par value; 1,000,000,000 shares authorized, 191,754,292 shares issued and outstanding at March 31, 2023; 1,000,000,000 shares authorized, 190,473,595 issued and outstanding at March 25, 2022 | 1,918 | 1,905 | |||||||||
Additional paid-in capital | 674,179 | 627,792 | |||||||||
Retained earnings | 310,315 | 122,958 | |||||||||
Accumulated other comprehensive loss | (20,784) | (18,448) | |||||||||
Equity attributable to Allegro MicroSystems, Inc. | 965,628 | 734,207 | |||||||||
Non-controlling interests | 1,187 | 1,156 | |||||||||
Total stockholders' equity | 966,815 | 735,363 | |||||||||
Total liabilities, non-controlling interests and stockholders' equity | $ | 1,181,155 | $ | 892,620 |
Fiscal Year Ended | |||||||||||
March 31, 2023 | March 25, 2022 | ||||||||||
(Unaudited) | |||||||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||||||
Net income | $ | 187,494 | $ | 119,555 | |||||||
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
Depreciation and amortization | 50,808 | 48,527 | |||||||||
Amortization of deferred financing costs | 99 | 101 | |||||||||
Deferred income taxes | (40,116) | 7,498 | |||||||||
Stock-based compensation | 61,798 | 33,548 | |||||||||
Loss (gain) on disposal of assets | 285 | (349) | |||||||||
Change in fair value of contingent consideration | (2,800) | (2,000) | |||||||||
Provisions for inventory and receivables reserves | (1,438) | 6,297 | |||||||||
Unrealized gains on marketable securities | (7,471) | (3,722) | |||||||||
Changes in operating assets and liabilities: | |||||||||||
Trade accounts receivable | (12,484) | (18,347) | |||||||||
Accounts payable (receivable) - other | 2,226 | (2,668) | |||||||||
Inventories | (75,150) | (4,471) | |||||||||
Prepaid expenses and other assets | (23,263) | (19,450) | |||||||||
Trade accounts payable | 11,958 | (4,348) | |||||||||
Due to/from related parties | 18,326 | (659) | |||||||||
Accrued expenses and other current and long-term liabilities | 22,934 | (3,383) | |||||||||
Net cash provided by operating activities | 193,206 | 156,129 | |||||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||||||
Purchases of property, plant and equipment | (79,775) | (69,941) | |||||||||
Acquisition of business, net of cash acquired | (19,921) | (14,549) | |||||||||
Proceeds from sales of property, plant and equipment | — | 27,408 | |||||||||
Investments in marketable securities | — | (9,189) | |||||||||
Net cash used in investing activities | (99,696) | (66,271) | |||||||||
CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||||||
Loans made to related party | (7,500) | (7,500) | |||||||||
Receipts on related party notes receivable | 2,812 | — | |||||||||
Proceeds from issuance of common stock under equity award and purchase plans less payments for taxes related to net share settlement of equity awards | (15,268) | 2,193 | |||||||||
Dividends paid to non-controlling interest | (42) | — | |||||||||
Net cash used in by financing activities | (19,998) | (5,307) | |||||||||
Effect of exchange rate changes on Cash and cash equivalents and Restricted cash | (4,606) | 1,373 | |||||||||
Net increase in Cash and cash equivalents and Restricted cash | 68,906 | 85,924 | |||||||||
Cash and cash equivalents and Restricted cash at beginning of period | 289,799 | 203,875 | |||||||||
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD: | $ | 358,705 | $ | 289,799 | |||||||
RECONCILIATION OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH: | |||||||||||
Cash and cash equivalents at beginning of period | $ | 282,383 | $ | 197,214 | |||||||
Restricted cash at beginning of period | 7,416 | 6,661 | |||||||||
Cash and cash equivalents and Restricted cash at beginning of period | $ | 289,799 | $ | 203,875 | |||||||
Cash and cash equivalents at end of period | 351,576 | 282,383 | |||||||||
Restricted cash at end of period | 7,129 | 7,416 | |||||||||
Cash and cash equivalents and Restricted cash at end of period | $ | 358,705 | $ | 289,799 | |||||||
Three-Month Period Ended | Fiscal Year Ended | |||||||||||||||||||||||||||||||
March 31, 2023 | December 23, 2022 | March 25, 2022 | March 31, 2023 | March 25, 2022 | ||||||||||||||||||||||||||||
(Dollars in thousands) | ||||||||||||||||||||||||||||||||
Reconciliation of Non-GAAP Gross Profit | ||||||||||||||||||||||||||||||||
GAAP Gross Profit | $ | 153,089 | $ | 142,594 | $ | 109,603 | $ | 546,079 | $ | 407,460 | ||||||||||||||||||||||
Voxtel inventory impairment | — | — | — | — | 3,106 | |||||||||||||||||||||||||||
Stock-based compensation | 1,978 | 1,156 | 1,184 | 5,090 | 3,176 | |||||||||||||||||||||||||||
AMTC Facility consolidation one-time costs | — | — | — | — | 144 | |||||||||||||||||||||||||||
Amortization of acquisition-related intangible assets | 627 | 589 | 273 | 1,867 | 1,092 | |||||||||||||||||||||||||||
COVID-19 related expenses | — | — | 296 | — | 1,092 | |||||||||||||||||||||||||||
Total Non-GAAP Adjustments | $ | 2,605 | $ | 1,745 | $ | 1,753 | $ | 6,957 | $ | 8,610 | ||||||||||||||||||||||
Non-GAAP Gross Profit | $ | 155,694 | $ | 144,339 | $ | 111,356 | $ | 553,036 | $ | 416,070 | ||||||||||||||||||||||
Non-GAAP Gross Margin | 57.8% | 58.0% | 55.6% | 56.8% | 54.1% | |||||||||||||||||||||||||||
Three-Month Period Ended | Fiscal Year Ended | |||||||||||||||||||||||||||||||
March 31, 2023 | December 23, 2022 | March 25, 2022 | March 31, 2023 | March 25, 2022 | ||||||||||||||||||||||||||||
(Dollars in thousands) | ||||||||||||||||||||||||||||||||
Reconciliation of Non-GAAP Operating Expenses | ||||||||||||||||||||||||||||||||
GAAP Operating Expenses | $ | 89,985 | $ | 76,966 | $ | 79,354 | $ | 342,772 | $ | 270,810 | ||||||||||||||||||||||
Research and Development Expenses | ||||||||||||||||||||||||||||||||
GAAP Research and Development Expenses | 41,833 | 39,593 | 32,432 | 150,850 | 121,873 | |||||||||||||||||||||||||||
Stock-based compensation | 3,483 | 3,174 | 1,119 | 9,496 | 3,933 | |||||||||||||||||||||||||||
AMTC Facility consolidation one-time costs | — | — | — | — | 2 | |||||||||||||||||||||||||||
COVID-19 related expenses | — | — | 3 | — | 23 | |||||||||||||||||||||||||||
Transaction fees | — | 1 | 5 | 404 | 5 | |||||||||||||||||||||||||||
Severance | 72 | — | — | 72 | — | |||||||||||||||||||||||||||
Non-GAAP Research and Development Expenses | 38,278 | 36,418 | 31,305 | 140,878 | 117,910 | |||||||||||||||||||||||||||
Selling, General and Administrative Expenses | ||||||||||||||||||||||||||||||||
GAAP Selling, General and Administrative Expenses | 48,252 | 37,373 | 46,822 | 194,722 | 150,937 | |||||||||||||||||||||||||||
Stock-based compensation | 5,095 | 4,572 | 12,598 | 47,212 | 26,439 | |||||||||||||||||||||||||||
AMTC Facility consolidation one-time costs | 124 | 291 | 74 | 601 | 657 | |||||||||||||||||||||||||||
Amortization of acquisition-related intangible assets | 22 | 23 | 22 | 90 | 90 | |||||||||||||||||||||||||||
COVID-19 related expenses | — | — | 215 | — | 1,503 | |||||||||||||||||||||||||||
Indirect transaction tax | 944 | — | — | 944 | — | |||||||||||||||||||||||||||
Transaction fees | 644 | 35 | 384 | 2,339 | 1,498 | |||||||||||||||||||||||||||
Sanken agreement termination fee | 5,000 | — | — | 5,000 | — | |||||||||||||||||||||||||||
Severance | 368 | — | — | 4,554 | 746 | |||||||||||||||||||||||||||
Non-GAAP Selling, General and Administrative Expenses | 36,055 | 32,452 | 33,529 | 133,982 | 120,004 | |||||||||||||||||||||||||||
Change in fair value of contingent consideration | (100) | — | 100 | (2,800) | (2,000) | |||||||||||||||||||||||||||
Total Non-GAAP Adjustments | 15,652 | 8,096 | 14,520 | 67,912 | 32,896 | |||||||||||||||||||||||||||
Non-GAAP Operating Expenses | $ | 74,333 | $ | 68,870 | $ | 64,834 | $ | 274,860 | $ | 237,914 |
Three-Month Period Ended | Fiscal Year Ended | |||||||||||||||||||||||||||||||
March 31, 2023 | December 23, 2022 | March 25, 2022 | March 31, 2023 | March 25, 2022 | ||||||||||||||||||||||||||||
(Dollars in thousands) | ||||||||||||||||||||||||||||||||
Reconciliation of Non-GAAP Operating Income | ||||||||||||||||||||||||||||||||
GAAP Operating Income | $ | 63,104 | $ | 65,628 | $ | 30,249 | $ | 203,307 | $ | 136,650 | ||||||||||||||||||||||
Voxtel inventory impairment | — | — | — | — | 3,106 | |||||||||||||||||||||||||||
Stock-based compensation | 10,556 | 8,902 | 14,901 | 61,798 | 33,548 | |||||||||||||||||||||||||||
AMTC Facility consolidation one-time costs | 124 | 291 | 74 | 601 | 803 | |||||||||||||||||||||||||||
Amortization of acquisition-related intangible assets | 649 | 612 | 295 | 1,957 | 1,182 | |||||||||||||||||||||||||||
COVID-19 related expenses | — | — | 514 | — | 2,618 | |||||||||||||||||||||||||||
Change in fair value of contingent consideration | (100) | — | 100 | (2,800) | (2,000) | |||||||||||||||||||||||||||
Indirect transaction tax | 944 | — | — | 944 | — | |||||||||||||||||||||||||||
Transaction fees | 644 | 36 | 389 | 2,743 | 1,503 | |||||||||||||||||||||||||||
Sanken agreement termination fee | 5,000 | — | — | 5,000 | — | |||||||||||||||||||||||||||
Severance | 440 | — | — | 4,626 | 746 | |||||||||||||||||||||||||||
Total Non-GAAP Adjustments | $ | 18,257 | $ | 9,841 | $ | 16,273 | $ | 74,869 | $ | 41,506 | ||||||||||||||||||||||
Non-GAAP Operating Income | $ | 81,361 | $ | 75,469 | $ | 46,522 | $ | 278,176 | $ | 178,156 | ||||||||||||||||||||||
Non-GAAP Operating Margin (% of net sales) | 30.2% | 30.3% | 23.2% | 28.6% | 23.2% | |||||||||||||||||||||||||||
Three-Month Period Ended | Fiscal Year Ended | |||||||||||||||||||||||||||||||
March 31, 2023 | December 23, 2022 | March 25, 2022 | March 31, 2023 | March 25, 2022 | ||||||||||||||||||||||||||||
(Dollars in thousands) | ||||||||||||||||||||||||||||||||
Reconciliation of EBITDA and Adjusted EBITDA | ||||||||||||||||||||||||||||||||
GAAP Net Income | $ | 62,012 | $ | 64,551 | $ | 25,652 | $ | 187,494 | $ | 119,555 | ||||||||||||||||||||||
Interest expense | 755 | 613 | 418 | 2,336 | 2,499 | |||||||||||||||||||||||||||
Interest income | (580) | (360) | (1,125) | (1,724) | (1,442) | |||||||||||||||||||||||||||
Income tax provision | 5,909 | 7,540 | 4,504 | 23,852 | 21,191 | |||||||||||||||||||||||||||
Depreciation & amortization | 14,103 | 12,580 | 12,006 | 50,808 | 48,527 | |||||||||||||||||||||||||||
EBITDA | $ | 82,199 | $ | 84,924 | $ | 41,455 | $ | 262,766 | $ | 190,330 | ||||||||||||||||||||||
Non-core (gain) loss on sale of equipment | (2) | 37 | 1 | 285 | (349) | |||||||||||||||||||||||||||
Voxtel inventory impairment | — | — | — | — | 3,106 | |||||||||||||||||||||||||||
Foreign currency translation loss (gain) | 1,617 | (407) | 513 | (980) | 568 | |||||||||||||||||||||||||||
(Loss) income in earnings of equity investment | 703 | (2,190) | (215) | 406 | (1,007) | |||||||||||||||||||||||||||
Unrealized (gains) losses on investments | (7,476) | (3,453) | 760 | (7,471) | (3,722) | |||||||||||||||||||||||||||
Stock-based compensation | 10,556 | 8,902 | 14,901 | 61,798 | 33,548 | |||||||||||||||||||||||||||
AMTC Facility consolidation one-time costs | 124 | 291 | 74 | 601 | 803 | |||||||||||||||||||||||||||
COVID-19 related expenses | — | — | 514 | — | 2,618 | |||||||||||||||||||||||||||
Change in fair value of contingent consideration | (100) | — | 100 | (2,800) | (2,000) | |||||||||||||||||||||||||||
Indirect transaction tax | 944 | — | — | 944 | — | |||||||||||||||||||||||||||
Transaction fees | 644 | 36 | 389 | 2,743 | 1,503 | |||||||||||||||||||||||||||
Sanken agreement termination fee | 5,000 | — | — | 5,000 | — | |||||||||||||||||||||||||||
Severance | 440 | — | — | 4,626 | 746 | |||||||||||||||||||||||||||
Adjusted EBITDA | $ | 94,649 | $ | 88,140 | $ | 58,492 | $ | 327,918 | $ | 226,144 | ||||||||||||||||||||||
Adjusted EBITDA Margin (% of net sales) | 35.1% | 35.4% | 29.2% | 33.7% | 29.4% | |||||||||||||||||||||||||||
Three-Month Period Ended | Fiscal Year Ended | |||||||||||||||||||||||||||||||
March 31, 2023 | December 23, 2022 | March 25, 2022 | March 31, 2023 | March 25, 2022 | ||||||||||||||||||||||||||||
(Dollars in thousands) | ||||||||||||||||||||||||||||||||
Reconciliation of Non-GAAP Profit before Tax | ||||||||||||||||||||||||||||||||
GAAP Income before Income Taxes | $ | 67,921 | $ | 72,091 | $ | 30,156 | $ | 211,346 | $ | 140,746 | ||||||||||||||||||||||
Non-core (gain) loss on sale of equipment | (2) | 37 | 1 | 285 | (349) | |||||||||||||||||||||||||||
Voxtel inventory impairment | — | — | — | — | 3,106 | |||||||||||||||||||||||||||
Foreign currency translation loss (gain) | 1,617 | (407) | 513 | (980) | 568 | |||||||||||||||||||||||||||
(Loss) income in earnings of equity investment | 703 | (2,190) | (215) | 406 | (1,007) | |||||||||||||||||||||||||||
Unrealized (gains) losses on investments | (7,476) | (3,453) | 760 | (7,471) | (3,722) | |||||||||||||||||||||||||||
Stock-based compensation | 10,556 | 8,902 | 14,901 | 61,798 | 33,548 | |||||||||||||||||||||||||||
AMTC Facility consolidation one-time costs | 124 | 291 | 74 | 601 | 803 | |||||||||||||||||||||||||||
Amortization of acquisition-related intangible assets | 649 | 612 | 295 | 1,957 | 1,182 | |||||||||||||||||||||||||||
COVID-19 related expenses | — | — | 514 | — | 2,618 | |||||||||||||||||||||||||||
Change in fair value of contingent consideration | (100) | — | 100 | (2,800) | (2,000) | |||||||||||||||||||||||||||
Indirect transaction tax | 944 | — | — | 944 | — | |||||||||||||||||||||||||||
Transaction fees | 644 | 36 | 389 | 2,743 | 1,503 | |||||||||||||||||||||||||||
Sanken agreement termination fee | 5,000 | — | — | 5,000 | — | |||||||||||||||||||||||||||
Severance | 440 | — | — | 4,626 | 746 | |||||||||||||||||||||||||||
Total Non-GAAP Adjustments | $ | 13,099 | $ | 3,828 | $ | 17,332 | $ | 67,109 | $ | 36,996 | ||||||||||||||||||||||
Non-GAAP Profit before Tax | $ | 81,020 | $ | 75,919 | $ | 47,488 | $ | 278,455 | $ | 177,742 | ||||||||||||||||||||||
Three-Month Period Ended | Fiscal Year Ended | |||||||||||||||||||||||||||||||
March 31, 2023 | December 23, 2022 | March 25, 2022 | March 31, 2023 | March 25, 2022 | ||||||||||||||||||||||||||||
(Dollars in thousands) | ||||||||||||||||||||||||||||||||
Reconciliation of Non-GAAP Provision for Income Taxes | ||||||||||||||||||||||||||||||||
GAAP Income Tax Provision | $ | 5,909 | $ | 7,540 | $ | 4,504 | $ | 23,852 | $ | 21,191 | ||||||||||||||||||||||
GAAP effective tax rate | 8.7% | 10.5% | 14.9% | 11.3% | 15.1% | |||||||||||||||||||||||||||
Tax effect of adjustments to GAAP results | 3,509 | (461) | 2,817 | 7,285 | 6,415 | |||||||||||||||||||||||||||
Non-GAAP Provision for Income Taxes | $ | 9,418 | $ | 7,079 | $ | 7,321 | $ | 31,137 | $ | 27,606 | ||||||||||||||||||||||
Non-GAAP effective tax rate | 11.6% | 9.3% | 15.4% | 11.2% | 15.5% | |||||||||||||||||||||||||||
Three-Month Period Ended | Fiscal Year Ended | |||||||||||||||||||||||||||||||
March 31, 2023 | December 23, 2022 | March 25, 2022 | March 31, 2023 | March 25, 2022 | ||||||||||||||||||||||||||||
(Dollars in thousands) | ||||||||||||||||||||||||||||||||
Reconciliation of Non-GAAP Net Income | ||||||||||||||||||||||||||||||||
GAAP Net Income | $ | 62,012 | $ | 64,551 | $ | 25,652 | $ | 187,494 | $ | 119,555 | ||||||||||||||||||||||
GAAP Basic Earnings per Share | $ | 0.32 | $ | 0.34 | $ | 0.14 | $ | 0.98 | $ | 0.63 | ||||||||||||||||||||||
GAAP Diluted Earnings per Share | $ | 0.32 | $ | 0.33 | $ | 0.13 | $ | 0.97 | $ | 0.62 | ||||||||||||||||||||||
Non-core (gain) loss on sale of equipment | (2) | 37 | 1 | 285 | (349) | |||||||||||||||||||||||||||
Voxtel inventory impairment | — | — | — | — | 3,106 | |||||||||||||||||||||||||||
Foreign currency translation loss (gain) | 1,617 | (407) | 513 | (980) | 568 | |||||||||||||||||||||||||||
(Loss) income in earnings of equity investment | 703 | (2,190) | (215) | 406 | (1,007) | |||||||||||||||||||||||||||
Unrealized (gains) losses on investments | (7,476) | (3,453) | 760 | (7,471) | (3,722) | |||||||||||||||||||||||||||
Stock-based compensation | 10,556 | 8,902 | 14,901 | 61,798 | 33,548 | |||||||||||||||||||||||||||
AMTC Facility consolidation one-time costs | 124 | 291 | 74 | 601 | 803 | |||||||||||||||||||||||||||
Amortization of acquisition-related intangible assets | 649 | 612 | 295 | 1,957 | 1,182 | |||||||||||||||||||||||||||
COVID-19 related expenses | — | — | 514 | — | 2,618 | |||||||||||||||||||||||||||
Change in fair value of contingent consideration | (100) | — | 100 | (2,800) | (2,000) | |||||||||||||||||||||||||||
Indirect transaction tax | 944 | — | — | 944 | — | |||||||||||||||||||||||||||
Transaction fees | 644 | 36 | 389 | 2,743 | 1,503 | |||||||||||||||||||||||||||
Sanken agreement termination fee | 5,000 | — | — | 5,000 | — | |||||||||||||||||||||||||||
Severance | 440 | — | — | 4,626 | 746 | |||||||||||||||||||||||||||
Tax effect of adjustments to GAAP results | (3,509) | 461 | (2,817) | (7,285) | (6,415) | |||||||||||||||||||||||||||
Non-GAAP Net Income | $ | 71,602 | $ | 68,840 | $ | 40,167 | $ | 247,318 | $ | 150,136 | ||||||||||||||||||||||
Basic weighted average common shares | 191,519,850 | 191,328,538 | 189,997,738 | 191,197,452 | 189,748,427 | |||||||||||||||||||||||||||
Diluted weighted average common shares | 194,993,241 | 193,935,908 | 192,125,252 | 193,688,102 | 191,811,205 | |||||||||||||||||||||||||||
Non-GAAP Basic Earnings per Share | $ | 0.37 | $ | 0.36 | $ | 0.21 | $ | 1.29 | $ | 0.79 | ||||||||||||||||||||||
Non-GAAP Diluted Earnings per Share | $ | 0.37 | $ | 0.35 | $ | 0.21 | $ | 1.28 | $ | 0.78 | ||||||||||||||||||||||